Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects.

Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE, Bekris LM, Raskind MA, Galasko DR, Montine TJ.

PLoS One. 2009;4(5):e5424. doi: 10.1371/journal.pone.0005424. Epub 2009 May 1.

2.

APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease.

Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Rembach A, Martins RN, Rowe CC, Masters CL, Maruff P.

Mol Psychiatry. 2015 Nov;20(11):1322-8. doi: 10.1038/mp.2014.123. Epub 2014 Oct 7.

3.

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E.

J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1080-6. doi: 10.1136/jnnp.2009.199950. Epub 2010 Jun 14.

PMID:
20547614
4.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
5.

Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease.

Forlenza OV, Diniz BS, Teixeira AL, Radanovic M, Talib LL, Rocha NP, Gattaz WF.

Neuromolecular Med. 2015 Sep;17(3):326-32. doi: 10.1007/s12017-015-8361-y. Epub 2015 Jul 3.

PMID:
26138246
6.

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.

Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, Nielsen HM.

Acta Neuropathol. 2014 May;127(5):633-43. doi: 10.1007/s00401-014-1266-2. Epub 2014 Mar 15.

PMID:
24633805
7.

Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease.

Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ.

Parkinsonism Relat Disord. 2011 Jan;17(1):61-4. doi: 10.1016/j.parkreldis.2010.10.003. Epub 2010 Nov 1.

8.

Decreased Neurotrophic Support is Associated with Cognitive Decline in Non-Demented Subjects.

Forlenza OV, Miranda AS, Guimar I, Talib LL, Diniz BS, Gattaz WF, Teixeira AL.

J Alzheimers Dis. 2015;46(2):423-9. doi: 10.3233/JAD-150172.

PMID:
25737042
9.

Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span.

Li G, Millard SP, Peskind ER, Zhang J, Yu CE, Leverenz JB, Mayer C, Shofer JS, Raskind MA, Quinn JF, Galasko DR, Montine TJ.

JAMA Neurol. 2014 Jun;71(6):742-51. doi: 10.1001/jamaneurol.2014.445.

10.

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.

Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM.

Biol Psychiatry. 2004 Nov 1;56(9):670-6.

PMID:
15522251
11.

Apolipoprotein E epsilon 4 allele in association with global cognitive performance and CSF markers in Alzheimer's disease.

Lasser RA, Dukoff R, Levy J, Levin R, Lehtimäki T, Seubert P, Sunderland T.

Int J Geriatr Psychiatry. 1998 Nov;13(11):767-74.

PMID:
9850873
12.

Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease.

Haldenwanger A, Eling P, Kastrup A, Hildebrandt H.

J Alzheimers Dis. 2010;22(3):971-80. doi: 10.3233/JAD-2010-101203.

PMID:
20858947
13.

Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.

J Alzheimers Dis. 2010;21(2):471-8. doi: 10.3233/JAD-2010-091594.

PMID:
20555147
14.

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.

Mol Psychiatry. 2004 Jul;9(7):705-10.

PMID:
14699432
15.

CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease.

Liguori C, Stefani A, Sancesario G, Sancesario GM, Marciani MG, Pierantozzi M.

J Neurol Neurosurg Psychiatry. 2015 Jun;86(6):655-9. doi: 10.1136/jnnp-2014-308577. Epub 2014 Aug 13.

PMID:
25121572
16.

Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.

Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E.

Arch Neurol. 2010 Feb;67(2):217-23. doi: 10.1001/archneurol.2009.316.

PMID:
20142530
17.

Reduced cerebrospinal fluid levels of brain-derived neurotrophic factor is associated with cognitive impairment in late-life major depression.

Diniz BS, Teixeira AL, Machado-Vieira R, Talib LL, Radanovic M, Gattaz WF, Forlenza OV.

J Gerontol B Psychol Sci Soc Sci. 2014 Nov;69(6):845-51. doi: 10.1093/geronb/gbu096. Epub 2014 Aug 22.

18.

Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.

Ewers M, Zhong Z, Bürger K, Wallin A, Blennow K, Teipel SJ, Shen Y, Hampel H.

Brain. 2008 May;131(Pt 5):1252-8. doi: 10.1093/brain/awn034. Epub 2008 Mar 11.

PMID:
18334538
19.

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.

van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.

Neurology. 2009 Mar 24;72(12):1056-61. doi: 10.1212/01.wnl.0000345014.48839.71.

PMID:
19307538
20.

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM.

Arch Neurol. 2009 May;66(5):638-45. doi: 10.1001/archneurol.2009.55.

Supplemental Content

Support Center